Fabrazyme is used to treat patients with Fabry disease, a disorder that results from a deficiency in the enzyme alpha-galactosidase A or alpha- GAL. Fabrazyme is infused with the purpose of replacing the missing enzyme in the patient. Fabrazyme works by lowering the amount of globotriaosylceramide (GL-3) which builds up in cells, lining the blood vessels of the kidney. Fabrazyme is infused every two weeks intravenously with the dosage depending on the patient’s body weight.


Copyright © 2021 Infusion and Immunotherapy Center of South Florida